Pros

LL Flooring Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 1, 2024
Interior Design, Architecture, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Social media, NPS, Traction, Ageing, LL, Transport, Pro, Deleveraging, Weakness, Advertising, Capital expenditure, GAAP, CRM, Credit, Environment, Pros

LL Flooring Holdings, Inc. (“LL Flooring” or “Company”) (NYSE: LL), a leading specialty retailer of hard and soft surface flooring in the U.S., today announced financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • LL Flooring Holdings, Inc. (“LL Flooring” or “Company”) (NYSE: LL), a leading specialty retailer of hard and soft surface flooring in the U.S., today announced financial results for the fourth quarter and year ended December 31, 2023.
  • Operating margin loss increased 170 basis points to 8.3% compared to the fourth quarter of last year.
  • Adjusted operating margin loss1 increased 550 basis points to 8.6% compared to the fourth quarter of last year.
  • Loss per Diluted Share increased $0.09 to $0.62 compared to the fourth quarter of last year.

EMA and European Organisation for Research and Treatment of Cancer (EORTC) workshop: How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions?, Online, European Medicines Agency, Amsterdam, t[...]

Retrieved on: 
Sunday, March 10, 2024
Pros, EMA, PRO, Research, Facilitation, Quality of life (healthcare), Treatment, Location, European Medicines Agency, Patient, HRQOL, Medical device

This workshop will bring together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry.

Key Points: 
  • This workshop will bring together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry.
  • The aims of the workshop are to:
    - Understand the current global landscape on the use of PROs and HRQOL for evaluation of anti-cancer treatments across different stakeholder groups.
  • - Understand the use of validated PRO questionnaires to measure core HRQOL outcomes and disease-related symptoms; and PRO Item Libraries in the development of trial-specific/treatment-specific item lists.
  • The recording of this meeting will be made available after the event.

Revolutionizing Trading Education: Trade With the Pros Introduces Unique Approach

Retrieved on: 
Tuesday, February 13, 2024
Education, Knowledge, Learning, Pros, Student, Tourism

Trade With the Pros recognizes that not everyone has experience in trading, to address this the company offers free live workshops.

Key Points: 
  • Trade With the Pros recognizes that not everyone has experience in trading, to address this the company offers free live workshops.
  • At Trade With the Pros, the key differentiator is a steadfast dedication to providing unparalleled learning experiences.
  • **Expert-Led Learning:** Trade With the Pros stands out by offering learning experiences curated by a team of seasoned professionals.
  • Trade With the Pros is a leading trading education platform committed to providing a unique and empowering learning experience.

SOUNDSTR'S #MUSICREVOLUTION CONTINUES

Retrieved on: 
Tuesday, February 6, 2024
Attention, Restaurant, MRT, Music, Pros, Collection, Radio, OTC, Lupino, Water, Electricity, Organization

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- VNUE, Inc. (OTC: VNUE) is actively working to change how music royalties are tracked and paid.

Key Points: 
  • "They [the PROs] come in here and demand a large licensing fee for music that we don't even use," said Lupino.
  • "Most of our musicians that come through are young original artists, whose music isn't even associated with a rights organization yet.
  • This means that 30% of all royalties collected seemingly doesn't even hit the pockets of the folks the PROs represent."
  • I believe Soundstr will help to fix this, and I am stoked to be a part of this #musicrevolution!"

AMERIPEN Launches 2024 EPR Webinar Series: Preparing for Packaging Producer Responsibility in the U.S.

Retrieved on: 
Monday, February 5, 2024
Policy, Hearing, Science, Environment, PRO, Pros, Learning, Public policy, American Institute, Data collection, EPR, Organization, Music

Washington, D.C., Feb. 05, 2024 (GLOBE NEWSWIRE) -- AMERIPEN , the American Institute for Packaging and the Environment, today announced a five-part webinar series, “Preparing for Packaging Producer Responsibility in the U.S.,” designed to help organizations set the groundwork for complying with extended producer responsibility (EPR) programs in the U.S.

Key Points: 
  • Washington, D.C., Feb. 05, 2024 (GLOBE NEWSWIRE) -- AMERIPEN , the American Institute for Packaging and the Environment, today announced a five-part webinar series, “Preparing for Packaging Producer Responsibility in the U.S.,” designed to help organizations set the groundwork for complying with extended producer responsibility (EPR) programs in the U.S.
  • Packaging producer responsibility will officially begin in the U.S. in July 2025 when Colorado and Oregon start collecting fees from producers.
  • Participants will rotate through different virtual rooms, hearing from various service providers specializing in packaging producer responsibility data and compliance.
  • Packaging producer responsibility may be new to the U.S., but it’s been implemented and amended for years in many other countries.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
Monday, February 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Retrieved on: 
Monday, February 5, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Gemcitabine, Quality of life, Rated R, Docetaxel, NAI, NMIBC, Patient, Safety, CIS, UCLA, DSS, Pros, PRO, Incidence, Progression-free survival, Cancer, Diagnosis, FDA, SOC, Medicine, Cystectomy, Global health, Experiment (probability theory), DFS, Pembrolizumab, Carcinoma in situ, PDUFA, Associate, Bladder cancer, BCG, BLA, Bacillus

Overall, participants who achieved a complete response with the novel combination therapy reported better physical function by month six of the study than those who did not achieve a complete response.

Key Points: 
  • Overall, participants who achieved a complete response with the novel combination therapy reported better physical function by month six of the study than those who did not achieve a complete response.
  • “Many current therapies for bladder cancer slow disease progression but can cause debilitating side effects,” said Principal Investigator Karim Chamie, M.D., Associate Professor of Urology at UCLA.
  • Bladder cancer is the 10th most-commonly diagnosed cancer, with approximately 80% of newly diagnosed cases being NMIBC.
  • Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

LOWE'S INVITES COMMUNITIES TO NOMINATE PROJECTS FOR LOWE'S HOMETOWNS GRANT PROGRAM

Retrieved on: 
Tuesday, January 23, 2024
Homelessness, Lionel Richie, Tuskegee University, Americans, Life, Electricity, Lowe's, Housing, Points of Light, Tuskegee Airmen, Veteran, Silent, The Tuskegee Airmen, Pros, Hearing, Tourism

MOORESVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- As part of Lowe's continued work to make communities better for all, the home improvement company is accepting project nominations for Lowe's Hometowns. Now in its third year, the five-year, $100 million impact program revitalizes community spaces including food pantries, veteran support programs, first responder facilities, affordable housing services and community gardens.

Key Points: 
  • Now through Feb. 19, people across the country are encouraged to go to Lowes.com/Hometowns to nominate a project to be part of Lowe's Hometowns.
  • This year, Lowe's associates will complete nearly 1,800 projects to improve their communities, including 100 signature grant projects selected through nominations and 1,700 selected by Lowe's associates.
  • "Lowe's Hometowns projects are helping to improve millions of lives across the country, and I'm excited to see the meaningful impact this program will make in 2024."
  • "This program creates a powerful and needed platform to build connections that serve to strengthen and benefit communities for years to come."

Rakuten Advertising Announces AI-Driven Partnership Discovery Solution to Connect Advertisers with the Most Effective Publisher Partners

Retrieved on: 
Tuesday, January 16, 2024
Rakuten, Classification, ASW, Filter, Rakuten Advertising, Intelligence, Society, Business model, Silver, Advertising, Cons, Pros, Marketing, News

LAS VEGAS, Jan. 16, 2024 /PRNewswire/ -- Rakuten Advertising, the leading global affiliate marketing network, revealed its plans to launch Partnership Discovery, the latest artificial intelligence investment as part of the company's Affiliate Intelligence platform and vision, at Affiliate Summit West 2024 in Las Vegas. Partnership Discovery leverages AI to help advertisers identify the most effective publisher partners for product-specific affiliate campaigns to drive higher audience engagement and more revenue. Publishers will also benefit from showcasing the strengths of their audiences to the advertisers for which they can deliver the strongest results.

Key Points: 
  • Partnership Discovery leverages AI to help advertisers identify the most effective publisher partners for product-specific affiliate campaigns to drive higher audience engagement and more revenue.
  • Offer advertisers alternative search terms and categories to find optimal publisher partners to reach audiences at both category and product levels.
  • "The launch of Partnership Discovery will bring Rakuten Advertising's vision for Affiliate Intelligence to life," says Nick Stamos, CEO of Rakuten Advertising.
  • Partnership: Filter by publisher status to identify new publisher partners, or re-engage existing partners to maximize reach, tap into new audiences, or re-engage with loyal shoppers.

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

Retrieved on: 
Monday, December 11, 2023
Telephone, Regeneron Pharmaceuticals, Quality of life, Food, Quality of life (healthcare), Treatment, Fever, DLBCL, EMA, FDA, CD20, Cytokine release syndrome, Dor, Anemia, Neutropenia, Pros, Orphan, Society, Research, B-cell lymphoma, ASH, Neuropsychological test, ICR, COVID-19, European Medicines Agency, ID, Fast track (FDA), University of Nantes, CRS, Webcast, Patient, Safety, Medicine, PFS, Pharmaceutical industry

TARRYTOWN, N.Y., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data for odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) from a pivotal Phase 2 trial (ELM-2). These data – which include updated efficacy, safety and patient-reported outcomes (PROs) – were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition from December 9 to 12 in San Diego, CA. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.

Key Points: 
  • Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
  • “As clinicians, our focus must remain patients’ wellbeing, along with favorable outcomes.
  • For odronextamab, it is particularly encouraging to see the unprecedented clinical results complemented by patient-reported outcomes that show quality of life and functional measures are maintained overall.
  • A replay of the conference call and webcast will be archived on the company's website for at least 30 days.